Drug Profile
Research programme: neurological disease therapies - UCB/ChemBridge Corporation
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ChemBridge Corporation; UCB
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders in Belgium (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders in USA (PO)
- 12 Jul 2007 Preclinical development is ongoing